Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.

Barry, Nathaniel; Francis, Roslyn J; Ebert, Martin A; Koh, Eng-Siew; Rowshanfarzad, Pejman; Hassan, Ghulam Mubashar; Kendrick, Jake; Gan, Hui K; Lee, Sze Ting; Lau, Eddie; Moffat, Bradford A; Fitt, Greg; Moore, Alisha; Thomas, Paul; Pattison, David A; Akhurst, Tim; Alipour, Ramin; Thomas, Elizabeth L; Hsiao, Edward; Schembri, Geoffrey P; Lin, Peter; Ly, Tam; Yap, June; Kirkwood, Ian; Vallat, Wilson; Khan, Shahroz; Krishna, Dayanethee; Ngai, Stanley; Yu, Chris; Beuzeville, Scott; Yeow, Tow C; Bailey, Dale; Cook, Olivia; Whitehead, Angela; Dykyj, Rachael; Rossi, Alana; Grose, Andrew; Scott, Andrew M

doi:10.1007/s00259-023-06371-5

Title

Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.

Publication Date

2023-11

Author(s)

Barry, Nathaniel

Francis, Roslyn J

Ebert, Martin A

Koh, Eng-Siew

Rowshanfarzad, Pejman

Hassan, Ghulam Mubashar

Kendrick, Jake

Gan, Hui K

Lee, Sze Ting

Lau, Eddie

Moffat, Bradford A

Fitt, Greg

Moore, Alisha

Thomas, Paul

Pattison, David A

Akhurst, Tim

Alipour, Ramin

Thomas, Elizabeth L

Hsiao, Edward

Schembri, Geoffrey P

Lin, Peter

Ly, Tam

Yap, June

Kirkwood, Ian

Vallat, Wilson

Khan, Shahroz

Krishna, Dayanethee

Ngai, Stanley

Yu, Chris

Beuzeville, Scott

Yeow, Tow C

Bailey, Dale

Cook, Olivia

Whitehead, Angela

Dykyj, Rachael

Rossi, Alana

Grose, Andrew

Scott, Andrew M

Subject

Clinical trials

Credentialing

FET PET

Glioblastoma

Inter-observer

Type of document

Journal Article

OrcId

0000-0002-9009-5909

#PLACEHOLDER_PARENT_METADATA_VALUE#

DOI

10.1007/s00259-023-06371-5

Abstract

The O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET in Glioblastoma (FIG) trial is an Australian prospective, multi-centre study evaluating FET PET for glioblastoma patient management. FET PET imaging timepoints are pre-chemoradiotherapy (FET1), 1-month post-chemoradiotherapy (FET2), and at suspected progression (FET3). Before participant recruitment, site nuclear medicine physicians (NMPs) underwent credentialing of FET PET delineation and image interpretation. Sites were required to complete contouring and dynamic analysis by ≥ 2 NMPs on benchmarking cases (n = 6) assessing biological tumour volume (BTV) delineation (3 × FET1) and image interpretation (3 × FET3). Data was reviewed by experts and violations noted. BTV definition includes tumour-to-background ratio (TBR) threshold of 1.6 with crescent-shaped background contour in the contralateral normal brain. Recurrence/pseudoprogression interpretation (FET3) required assessment of maximum TBR (TBRmax), dynamic analysis (time activity curve [TAC] type, time to peak), and qualitative assessment. Intraclass correlation coefficient (ICC) assessed volume agreement, coefficient of variation (CoV) compared maximum/mean TBR (TBRmax/TBRmean) across cases, and pairwise analysis assessed spatial (Dice similarity coefficient [DSC]) and boundary agreement (Hausdorff distance [HD], mean absolute surface distance [MASD]). Data was accrued from 21 NMPs (10 centres, n ≥ 2 each) and 20 underwent review. The initial pass rate was 93/119 (78.2%) and 27/30 requested resubmissions were completed. Violations were found in 25/72 (34.7%; 13/12 minor/major) of FET1 and 22/74 (29.7%; 14/8 minor/major) of FET3 reports. The primary reasons for resubmission were as follows: BTV over-contour (15/30, 50.0%), background placement (8/30, 26.7%), TAC classification (9/30, 30.0%), and image interpretation (7/30, 23.3%). CoV median and range for BTV, TBRmax, and TBRmean were 21.53% (12.00-30.10%), 5.89% (5.01-6.68%), and 5.01% (3.37-6.34%), respectively. BTV agreement was moderate to excellent (ICC = 0.82; 95% CI, 0.63-0.97) with good spatial (DSC = 0.84 ± 0.09) and boundary (HD = 15.78 ± 8.30 mm; MASD = 1.47 ± 1.36 mm) agreement. The FIG study credentialing program has increased expertise across study sites. TBRmax and TBRmean were robust, with considerable variability in BTV delineation and image interpretation observed.

Link

link

Citation

European Journal of Nuclear Medicine and Molecular Imaging 2023-11; 50(13)

Jornal Title

European Journal of Nuclear Medicine and Molecular Imaging

ISSN

1619-7089

Austin Health

Files: